{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:47:15Z","timestamp":1793504835235,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372072 82071986 and 81771827"],"award-info":[{"award-number":["82372072 82071986 and 81771827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with limited treatment options in advanced stages. Liensinine, a natural alkaloid derived from <jats:italic>Nelumbo nucifera<\/jats:italic>, has shown promise as an anticancer agent. However, its underlying mechanisms, particularly in modulating tumor metabolism and immune responses, remain poorly understood. This study aimed to investigate the antitumor effects of Liensinine in HCC, focusing on its ability to modulate metabolic pathways, immune responses, and the tumor microenvironment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>HCC cell lines (HUH7 and Hep1-6) were treated with Liensinine in vitro to assess cell viability, migration, proliferation, and apoptosis. Metabolic reprogramming was analyzed through RNA sequencing, Seahorse metabolic assays, and glucose\/lactate measurements. The effects on immune cells were studied by treating THP-1 macrophages and peripheral blood mononuclear cells (PBMCs) with conditioned media from Liensinine-treated cells. In vivo, subcutaneous xenograft and orthotopic liver cancer models were used to evaluate the therapeutic efficacy of Liensinine combination with radiotherapy and immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Liensinine inhibited HCC cell viability, migration, and proliferation, promoting apoptosis and shifting metabolism from glycolysis to oxidative phosphorylation. This metabolic reprogramming was linked to the activation of the AMPK-HIF-1\u03b1 axis and increased ROS production. Furthermore, Liensinine induced Endoplasmic reticulum (ER) stress, as evidenced by elevated levels of CHOP and ATF4, which contributed to AMPK activation and suppression of HIF-1\u03b1. Liensinine reduced PD-L1 expression, enhanced M1 macrophage polarization, and promoted CD8\u2009+\u2009T cell infiltration into tumors. In vivo, Liensinine significantly suppressed tumor growth, reduced vascular density, and reshaped the immune microenvironment by promoting M1 macrophage polarization. Combination therapy with Liensinine, radiotherapy, and immunotherapy resulted in synergistic effects, including enhanced tumor cell apoptosis, increased immune cell infiltration, and improved therapeutic efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Liensinine exerts potent antitumor effects in HCC by reprogramming tumor metabolism, inducing ER stress, enhancing immune responses, and modulating the TME. The combination of Liensinine with immunotherapy and radiotherapy significantly improves therapeutic efficacy, suggesting its potential as a novel treatment strategy for HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03477-6","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:31:00Z","timestamp":1752564660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1\u03b1 axis in hepatocellular carcinoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Jiahao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongpei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"1","key":"3477_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"Cancer J Clin"},{"issue":"9","key":"3477_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41568-021-00383-9","volume":"21","author":"X Li","year":"2021","unstructured":"Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21(9):541\u201357.","journal-title":"Nat Rev Cancer"},{"key":"3477_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-030-65768-0_9","volume":"1311","author":"J Salazar","year":"2021","unstructured":"Salazar J, Le A. The heterogeneity of liver Cancer metabolism. Adv Exp Med Biol. 2021;1311:127\u201336.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"3477_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","volume":"42","author":"H Yang","year":"2024","unstructured":"Yang H, Cheng J, Zhuang H, Xu H, Wang Y, Zhang T, et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell. 2024;42(4):535\u201351. e8.","journal-title":"Cancer Cell"},{"issue":"5","key":"3477_CR5","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1097\/HEP.0000000000000005","volume":"78","author":"F Yang","year":"2023","unstructured":"Yang F, Hilakivi-Clarke L, Shaha A, Wang Y, Wang X, Deng Y, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78(5):1602\u201324.","journal-title":"Hepatology"},{"issue":"1","key":"3477_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","volume":"17","author":"J Lin","year":"2024","unstructured":"Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17(1):6.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3477_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit Cancer cells?? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"key":"3477_CR8","doi-asserted-by":"crossref","unstructured":"Alberghina L. The Warburg effect explained: integration of enhanced Glycolysis with heterogeneous mitochondria to promote Cancer cell proliferation. Int J Mol Sci. 2023;24(21).","DOI":"10.3390\/ijms242115787"},{"issue":"8","key":"3477_CR9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.cmet.2024.07.011","volume":"36","author":"G Li","year":"2024","unstructured":"Li G, Wang D, Zhai Y, Pan C, Zhang J, Wang C, et al. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab. 2024;36(8):1696\u2013710. e10.","journal-title":"Cell Metab"},{"issue":"7","key":"3477_CR10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41401-022-01037-8","volume":"44","author":"SL Cai","year":"2023","unstructured":"Cai SL, Fan XG, Wu J, Wang Y, Hu XW, Pei SY, et al. CB2R agonist GW405833 alleviates acute liver failure in mice via inhibiting HIF-1alpha-mediated reprogramming of glycometabolism and macrophage proliferation. Acta Pharmacol Sin. 2023;44(7):1391\u2013403.","journal-title":"Acta Pharmacol Sin"},{"issue":"31","key":"3477_CR11","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1039\/D3SC01874A","volume":"14","author":"S Jin","year":"2023","unstructured":"Jin S, Yin E, Feng C, Sun Y, Yang T, Yuan H, et al. Regulating tumor glycometabolism and the immune microenvironment by inhibiting lactate dehydrogenase with platinum(iv) complexes. Chem Sci. 2023;14(31):8327\u201337.","journal-title":"Chem Sci"},{"issue":"4","key":"3477_CR12","doi-asserted-by":"publisher","first-page":"e2204808","DOI":"10.1002\/advs.202204808","volume":"10","author":"J Zhao","year":"2023","unstructured":"Zhao J, Tian Z, Zhao S, Feng D, Guo Z, Wen L, et al. Insights into the effect of catalytic intratumoral lactate depletion on metabolic reprogramming and immune activation for antitumoral activity. Adv Sci (Weinh). 2023;10(4):e2204808.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"3477_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/thno.28992","volume":"9","author":"YL Zheng","year":"2019","unstructured":"Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, et al. LINC01554-Mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting akt\/mtor signaling pathway. Theranostics. 2019;9(3):796\u2013810.","journal-title":"Theranostics"},{"key":"3477_CR14","doi-asserted-by":"crossref","unstructured":"Gong J, Zhou S, Yang S. Vanillic acid suppresses HIF-1alpha expression via Inhibition of mTOR\/p70S6K\/4E-BP1 and raf\/mek\/erk pathways in human Colon cancer HCT116 cells. Int J Mol Sci. 2019;20(3).","DOI":"10.3390\/ijms20030465"},{"key":"3477_CR15","doi-asserted-by":"crossref","unstructured":"Yuan Y, Long H, Zhou Z, Fu Y, Jiang B. PI3K-AKT-Targeting breast Cancer treatments: natural products and synthetic compounds. Biomolecules. 2023;13(1).","DOI":"10.3390\/biom13010093"},{"key":"3477_CR16","doi-asserted-by":"crossref","unstructured":"Guo J, Yan W, Duan H, Wang D, Zhou Y, Feng D et al. Therapeutic effects of natural products on liver Cancer and their potential mechanisms. Nutrients. 2024;16(11).","DOI":"10.3390\/nu16111642"},{"issue":"6","key":"3477_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/abbs\/gmz041","volume":"51","author":"Y Shen","year":"2019","unstructured":"Shen Y, Bian R, Li Y, Gao Y, Liu Y, Xu Y, et al. Liensinine induces gallbladder cancer apoptosis and G2\/M arrest by inhibiting ZFX-induced PI3K\/AKT pathway. Acta Biochim Biophys Sin (Shanghai). 2019;51(6):607\u201314.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"3477_CR18","doi-asserted-by":"publisher","first-page":"155647","DOI":"10.1016\/j.phymed.2024.155647","volume":"129","author":"Z Feng","year":"2024","unstructured":"Feng Z, Zhang S, Han Q, Chu T, Wang H, Yu L, et al. Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1alpha to inhibit autophagy. Phytomedicine. 2024;129:155647.","journal-title":"Phytomedicine"},{"key":"3477_CR19","doi-asserted-by":"publisher","first-page":"116871","DOI":"10.1016\/j.biopha.2024.116871","volume":"176","author":"X Lin","year":"2024","unstructured":"Lin X, Lin T, Liu M, Chen D, Chen J. Liensinine diperchlorate and Artemisitene synergistically attenuate breast cancer progression through suppressing PI3K-AKT signaling and their efficiency in breast cancer patient-derived organoids. Biomed Pharmacother. 2024;176:116871.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3477_CR20","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1021\/acs.jafc.3c06142","volume":"72","author":"B Ma","year":"2024","unstructured":"Ma B, Shi S, Guo W, Zhang H, Zhao Z, An H. Liensinine, a novel and Food-Derived compound, exerts potent antihepatoma efficacy via inhibiting the Kv10.1 channel. J Agric Food Chem. 2024;72(9):4689\u2013702.","journal-title":"J Agric Food Chem"},{"issue":"1","key":"3477_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12967-023-04312-2","volume":"21","author":"H Tan","year":"2023","unstructured":"Tan H, Liu J, Huang J, Li Y, Xie Q, Dong Y, et al. Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1. J Transl Med. 2023;21(1):462.","journal-title":"J Transl Med"},{"key":"3477_CR22","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.redox.2022.102344","volume":"53","author":"W Liu","year":"2022","unstructured":"Liu W, Zhao Y, Wang G, Feng S, Ge X, Ye W, et al. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ros\/ampk\/mtor\/autophagy signaling. Redox Biol. 2022;53:102344.","journal-title":"Redox Biol"},{"issue":"18","key":"3477_CR23","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1080\/15384101.2023.2247248","volume":"22","author":"W Wang","year":"2023","unstructured":"Wang W, Xu X, Zhao L, Ye K, Wang S, Lin C. 3,5-diCQA suppresses colorectal cancer cell growth through ros\/ampk\/mtor mediated mitochondrial dysfunction and ferroptosis. Cell Cycle. 2023;22(18):1951\u201368.","journal-title":"Cell Cycle"},{"key":"3477_CR24","doi-asserted-by":"publisher","first-page":"107451","DOI":"10.1016\/j.pharmthera.2019.107451","volume":"206","author":"TP Brown","year":"2020","unstructured":"Brown TP, Ganapathy V. Lactate\/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"3477_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41419-022-05341-3","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Hu T, Shen Z, Zheng Y, Geng Q, Li L, et al. Inhibition of USP1 activates ER stress through Ubi-protein aggregation to induce autophagy and apoptosis in HCC. Cell Death Dis. 2022;13(11):951.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3477_CR26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cmet.2020.05.004","volume":"31","author":"J Zhang","year":"2020","unstructured":"Zhang J, Muri J, Fitzgerald G, Gorski T, Gianni-Barrera R, Masschelein E, et al. Endothelial lactate controls muscle regeneration from ischemia by inducing M2-like macrophage polarization. Cell Metab. 2020;31(6):1136\u201353. e7.","journal-title":"Cell Metab"},{"key":"3477_CR27","doi-asserted-by":"publisher","first-page":"123810","DOI":"10.1016\/j.ijbiomac.2023.123810","volume":"237","author":"X Fang","year":"2023","unstructured":"Fang X, Zhao P, Gao S, Liu D, Zhang S, Shan M, et al. Lactate induces tumor-associated macrophage polarization independent of mitochondrial pyruvate carrier-mediated metabolism. Int J Biol Macromol. 2023;237:123810.","journal-title":"Int J Biol Macromol"},{"key":"3477_CR28","doi-asserted-by":"crossref","unstructured":"Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A. 2022;119(8).","DOI":"10.1073\/pnas.2114851119"},{"issue":"Pt A","key":"3477_CR29","doi-asserted-by":"publisher","first-page":"110905","DOI":"10.1016\/j.intimp.2023.110905","volume":"124","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wang J, Shang Y, Chen Y, Chen S, He Q. Boningmycin induces AMPK-mediated Endoplasmic reticulum-associated degradation of PD-L1 protein in human cancer cells. Int Immunopharmacol. 2023;124(Pt A):110905.","journal-title":"Int Immunopharmacol"},{"key":"3477_CR30","doi-asserted-by":"crossref","unstructured":"Shurin MR, Umansky V. Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy. J Clin Invest. 2022;132(9).","DOI":"10.1172\/JCI159473"},{"issue":"2","key":"3477_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","volume":"11","author":"LA Dawson","year":"2025","unstructured":"Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, et al. Stereotactic body radiotherapy vs Sorafenib alone in hepatocellular carcinoma: the NRG oncology\/rtog 1112 phase 3 randomized clinical trial. JAMA Oncol. 2025;11(2):136\u201344.","journal-title":"JAMA Oncol"},{"issue":"9","key":"3477_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/JCO-24-01532","volume":"43","author":"M Xi","year":"2025","unstructured":"Xi M, Yang Z, Hu L, Fu Y, Hu D, Zhou Z, et al. Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: A randomized, Open-Label, controlled trial. J Clin Oncol. 2025;43(9):1073\u201382.","journal-title":"J Clin Oncol"},{"key":"3477_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jconrel.2022.06.030","volume":"348","author":"J Liu","year":"2022","unstructured":"Liu J, Guo L, Mi Z, Liu Z, Rong P, Zhou W. Vascular bursts-mediated tumor accumulation and deep penetration of spherical nucleic acids for synergistic radio-immunotherapy. J Controlled Release: Official J Controlled Release Soc. 2022;348:1050\u201365.","journal-title":"J Controlled Release: Official J Controlled Release Soc"},{"issue":"1","key":"3477_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28.","journal-title":"Mol Cancer"},{"key":"3477_CR35","doi-asserted-by":"crossref","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487).","DOI":"10.1126\/science.aaw5473"},{"issue":"30","key":"3477_CR36","doi-asserted-by":"publisher","first-page":"e2202993","DOI":"10.1002\/advs.202202993","volume":"9","author":"X Li","year":"2022","unstructured":"Li X, Peng X, Zhang C, Bai X, Li Y, Chen G, et al. Bladder Cancer-Derived small extracellular vesicles promote tumor angiogenesis by inducing HBP-Related metabolic reprogramming and SerRS O-GlcNAcylation in endothelial cells. Adv Sci (Weinh). 2022;9(30):e2202993.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"3477_CR37","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in Cancer therapy. Clin Cancer Res. 2018;24(11):2482\u201390.","journal-title":"Clin Cancer Res"},{"key":"3477_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","volume":"502","author":"F Paredes","year":"2021","unstructured":"Paredes F, Williams HC, San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett. 2021;502:133\u201342.","journal-title":"Cancer Lett"},{"issue":"9","key":"3477_CR39","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1073\/pnas.1816391116","volume":"116","author":"D Jia","year":"2019","unstructured":"Jia D, Lu M, Jung KH, Park JH, Yu L, Onuchic JN, et al. Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc Natl Acad Sci U S A. 2019;116(9):3909\u201318.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3477_CR40","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/0008-5472.CAN-16-2074","volume":"77","author":"L Yu","year":"2017","unstructured":"Yu L, Lu M, Jia D, Ma J, Ben-Jacob E, Levine H, et al. Modeling the genetic regulation of Cancer metabolism: interplay between Glycolysis and oxidative phosphorylation. Cancer Res. 2017;77(7):1564\u201374.","journal-title":"Cancer Res"},{"key":"3477_CR41","doi-asserted-by":"crossref","unstructured":"Tyszka-Czochara M, Bukowska-Strakova K, Kocemba-Pilarczyk KA, Majka M. Caffeic acid targets AMPK signaling and regulates Tricarboxylic acid cycle anaplerosis while Metformin downregulates HIF-1alpha-Induced glycolytic enzymes in human cervical squamous cell carcinoma lines. Nutrients. 2018;10(7).","DOI":"10.3390\/nu10070841"},{"issue":"4","key":"3477_CR42","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1016\/j.bbrc.2017.12.141","volume":"495","author":"Y Murata","year":"2018","unstructured":"Murata Y, Hashimoto T, Urushihara Y, Shiga S, Takeda K, Jingu K, et al. Knockdown of ampkalpha decreases ATM expression and increases radiosensitivity under hypoxia and nutrient starvation in an SV40-transformed human fibroblast cell line, LM217. Biochem Biophys Res Commun. 2018;495(4):2566\u201372.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"3477_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-022-02252-1","volume":"41","author":"Y Chen","year":"2022","unstructured":"Chen Y, Liu L, Xia L, Wu N, Wang Y, Li H, et al. TRPM7 Silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1alpha degradation. J Exp Clin Cancer Res. 2022;41(1):44.","journal-title":"J Exp Clin Cancer Res"},{"key":"3477_CR44","doi-asserted-by":"publisher","first-page":"108855","DOI":"10.1016\/j.intimp.2022.108855","volume":"111","author":"H Jiang","year":"2022","unstructured":"Jiang H, Niu C, Guo Y, Liu Z, Jiang Y. Wedelolactone induces apoptosis and pyroptosis in retinoblastoma through promoting ROS generation. Int Immunopharmacol. 2022;111:108855.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"3477_CR45","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/cr.2015.68","volume":"25","author":"B Kelly","year":"2015","unstructured":"Kelly B, O\u2019Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771\u201384.","journal-title":"Cell Res"},{"issue":"1","key":"3477_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12964-022-00909-0","volume":"20","author":"G Ma","year":"2022","unstructured":"Ma G, Zhang Z, Li P, Zhang Z, Zeng M, Liang Z, et al. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. Cell Commun Signal. 2022;20(1):114.","journal-title":"Cell Commun Signal"},{"key":"3477_CR47","doi-asserted-by":"publisher","first-page":"15557","DOI":"10.1038\/ncomms15557","volume":"8","author":"C Morland","year":"2017","unstructured":"Morland C, Andersson KA, Haugen OP, Hadzic A, Kleppa L, Gille A, et al. Exercise induces cerebral VEGF and angiogenesis via the lactate receptor HCAR1. Nat Commun. 2017;8:15557.","journal-title":"Nat Commun"},{"key":"3477_CR48","first-page":"19","volume":"23","author":"L Chen","year":"2022","unstructured":"Chen L, Huang L, Gu Y, Cang W, Sun P, Xiang Y. Lactate-Lactylation hands between metabolic reprogramming and immunosuppression. Int J Mol Sci. 2022;23:19.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3477_CR49","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/1078-0432.CCR-22-3350","volume":"29","author":"K Chaudagar","year":"2023","unstructured":"Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, et al. Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN\/p53-deficient prostate Cancer. Clin Cancer Res. 2023;29(10):1952\u201368.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3477_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/08830185.2021.1955876","volume":"41","author":"HC Zhou","year":"2022","unstructured":"Zhou HC, Xin-Yan Y, Yu WW, Liang XQ, Du XY, Liu ZC, et al. Lactic acid in macrophage polarization: the significant role in inflammation and cancer. Int Rev Immunol. 2022;41(1):4\u201318.","journal-title":"Int Rev Immunol"},{"issue":"2","key":"3477_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21(2):71\u201388.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3477_CR52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.20517\/cdr.2023.60","volume":"6","author":"K Laubach","year":"2023","unstructured":"Laubach K, Turan T, Mathew R, Wilsbacher J, Engelhardt J, Samayoa J. Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1\/PD-L1 treatment. Cancer Drug Resist. 2023;6(3):611\u201341.","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"3477_CR53","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","volume":"71","author":"JH Cha","year":"2018","unstructured":"Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes antitumor immunity via Endoplasmic-Reticulum-Associated degradation of PD-L1. Mol Cell. 2018;71(4):606\u201320. e7.","journal-title":"Mol Cell"},{"issue":"3","key":"3477_CR54","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO oligocare consortium. Lancet Oncol. 2023;24(3):e121\u201332.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03477-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:53:12Z","timestamp":1757253192000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03477-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3477"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03477-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies and clinical samples were conducted in accordance with the Declaration of Helsinki and by the Ethics Committee of Xiangya Third Hospital, Central South University (22480).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approved"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}